LOW-DOSE ARA-C AS AN ALTERNATIVE THERAPY FOR OLDER PATIENTS WITH AML

被引：0
|
作者：
HEYLL, A [1 ]
AUL, C [1 ]
HEYLL, U [1 ]
FISCHER, JT [1 ]
SCHNEIDER, W [1 ]
机构：
[1] UNIV DUSSELDORF,KLIN A,MED KLIN & POLIKLIN,D-4000 DUSSELDORF,FED REP GER
来源：
BLUT | 1985年 / 51卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：163 / 163
页数：1
相关论文
共 50 条
  • [31] Low Dose Ara-C Versus Low Dose Ara-C and Tipifarnib: Result of the UK NCRI AML16 "Pick a Winner" Comparison
    Burnett, Alan K.
    Hills, Robert
    Milligan, Donald
    Kell, William J.
    Wheatley, Keith
    Virchis, Andres E.
    Russell, Nigel H.
    BLOOD, 2008, 112 (11) : 1017 - 1018
  • [32] A Randomised Evaluation of Low-Dose Ara-C Plus BCT-100 Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia: Results from the LI-1 Trial
    Mussai, Francis J.
    Thomas, Ian
    Ariti, Cono
    Upton, Laura
    Sydenham, Mia
    Burnett, Alan K.
    Knapper, Steve
    Mehta, Priyanka
    McMullin, Mary Frances
    Copland, Mhairi
    Russell, Nigel H.
    Hills, Robert
    BLOOD, 2021, 138
  • [33] Low Dose Ara-C Versus Low Dose Ara-C and Arsenic Trioxide: the UK NCRI AML16 "Pick a Winner" Comparison.
    Russell, Nigel H.
    Hills, Robert K.
    Hunter, Ann E.
    Milligan, Donald
    Kell, William J.
    Wheatley, Keith
    McMullin, Mary Frances
    Yin, John A. L.
    Bowen, David T.
    Burnett, A.
    BLOOD, 2009, 114 (22) : 201 - 201
  • [34] SUBCUTANEOUS LOW-DOSE CYTOSINE-ARABINOSIDE (ARA-C) IN PATIENTS WITH MYELODISPLASTIC SYNDROMES
    AVILES, A
    TRIPP, F
    VELASQUEZ, A
    RUBIO, ME
    GONZALEZLLAVEN, J
    REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION, 1988, 40 (01): : 21 - 24
  • [35] Intermittent intermediate dose ARA-C as consolidation therapy for AML in the elderly.
    Sperr, WR
    Piribauer, M
    Agis, H
    Mitterbauer, M
    Geissler, K
    Haas, O
    Fonatsch, C
    Jager, U
    Schwarzinger, I
    Thalhammer, F
    Valent, P
    Lechner, K
    BLOOD, 1997, 90 (10) : 2267 - 2267
  • [36] RELATIONSHIP OF [H-3] ARA-C INCORPORATION AND RESPONSE TO THERAPY WITH HIGH-DOSE ARA-C IN AML PATIENTS - A LEUKEMIA INTERGROUP STUDY
    RAZA, A
    GEZER, S
    ANDERSON, J
    LYKINS, J
    BENNETT, J
    BROWMAN, G
    GOLDBERG, J
    LARSON, R
    VOGLER, R
    PREISLER, HD
    EXPERIMENTAL HEMATOLOGY, 1992, 20 (10) : 1194 - 1200
  • [37] EFFECT OF LOW-DOSE ARA-C TREATMENT AND THE COMBINATION TREATMENT WITH LOW-DOSE ARA-C AND HYDROXYVITAMIN-D3 IN ACUTE NONLYMPHOCYTIC LEUKEMIA AND MYELODYSPLASTIC SYNDROME
    SAWADA, H
    ABE, T
    TASHIMA, M
    YOSHIDA, Y
    YAMAGISHI, M
    OKUDA, T
    YUMOTO, Y
    KATO, Y
    UCHINO, H
    MYELODYSPLASTIC SYNDROMES : PATHOPHYSIOLOGY AND TREATMENT, 1988, 783 : 205 - 214
  • [38] LOW-DOSE CYTARABINE (ARA-C) IN THE TREATMENT OF MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOID-LEUKEMIA (AML)
    MUFTI, GJ
    OSCIER, DG
    HAMBLIN, TJ
    BRITISH JOURNAL OF HAEMATOLOGY, 1985, 61 (03) : 571 - 571
  • [39] TREATMENT OF LEUKEMIA WITH LOW-DOSE ARA-C - A STUDY OF 160 CASES
    DEGOS, L
    CASTAIGNE, S
    TILLY, H
    SIGAUX, F
    DANIEL, MT
    SEMINARS IN ONCOLOGY, 1985, 12 (02) : 196 - 199
  • [40] LOW-DOSE CYTOSINE-ARABINOSIDE (ARA-C) IN MYELODYSPLASTIC SYNDROMES
    TRICOT, G
    DEBOCK, R
    DEKKER, AW
    BOOGAERTS, MA
    PEETERMANS, M
    PUNT, K
    VERWILGHEN, RL
    BRITISH JOURNAL OF HAEMATOLOGY, 1984, 58 (02) : 231 - 240
12345